GI
INDV icon

GAMMA Investing’s Indivior Pharmaceuticals INDV Stock Holding History

GAMMA Investing’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$42.8K Sell
1,193
-419
-26% -$15.8K ﹤0.01% 2472
2026
Q2 		$66.1K Buy
1,612
+1,115
+224% +$40.4K ﹤0.01% 2112
2026
Q1 		$15.1K Sell
497
-702
-59% -$23.2K ﹤0.01% 2866
2025
Q4 		$43K Buy
1,199
+1,013
+545% +$30.9K ﹤0.01% 2168
2025
Q3 		$4.48K Buy
+186
New +$3.89K ﹤0.01% 3217

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

GAMMA Investing's INDV Position: Q3 2026 in Review

GAMMA Investing reduced its Indivior Pharmaceuticals (INDV) stake by 26% in Q3 2026, selling an estimated $15.8K and leaving 1,193 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2472.

GAMMA Investing first reported a position in INDV in Q3 2025 and has held it in 5 quarters since. The position peaked at $66.1K in Q2 2026. 8 funds tracked by Wall St. Rank hold INDV as of Q3 2026.

  • GAMMA Investing held 1,193 shares of Indivior Pharmaceuticals worth $42.8K as of Q3 2026.
  • GAMMA Investing sold 419 Indivior Pharmaceuticals shares in Q3 2026, an estimated $15.8K.
  • Indivior Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2472 holding.
  • GAMMA Investing first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • GAMMA Investing's Indivior Pharmaceuticals position peaked at $66.1K in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.